Skip to search formSkip to main contentSkip to account menu

Megestrol Acetate

Known as: 6-Methyl-delta-4,6-pregnadien-17 alpha-ol-3,20-dione Acetate, 17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate, 17?-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate 
The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic… 
National Institutes of Health

Related topics

Related topics

28 relations
AnorexiaCachexiaDrug AllergyEndometrial Neoplasms
Expand

Broader (3)

Antineoplastic Agents, HormonalAppetite StimulantsMegestrol

Narrower (5)

BoreaMegaceMestrelNiagestin
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
Megestrol acetate for the treatment of anorexia-cachexia syndrome.
BACKGROUND Megestrol acetate (MA) is currently used to improve appetite and to increase weight in cancer-associated anorexia. In… 
Highly Cited
2004
Highly Cited
2004
An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada…
PURPOSE Studies suggest eicosapentaenoic acid (EPA), an omega-3 fatty acid, augments weight, appetite, and survival in cancer… 
Review
2003
Review
2003
Classification and pharmacology of progestins.
Highly Cited
2002
Highly Cited
2002
Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study.
PURPOSE To determine whether dronabinol administered alone or with megestrol acetate was more, less, or equal in efficacy to… 
Review
2002
Review
2002
Cancer Anorexia‐Cachexia Syndrome: Current Issues in Research and Management
  • A. Inui
  • CA: a cancer journal for clinicians
  • 2002
  • Corpus ID: 29298459
Cachexia is among the most debilitating and life‐threatening aspects of cancer. Associated with anorexia, fat and muscle tissue… 
Highly Cited
2001
Highly Cited
2001
Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
PURPOSE To compare two doses of letrozole (0.5 mg and 2.5 mg every day) and megestrol acetate (40 mg qid) as endocrine therapy in… 
Highly Cited
2000
Highly Cited
2000
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study…
PURPOSE This phase III, double-blind, randomized, multicenter study evaluated the efficacy, pharmacodynamics, and safety of the… 
Highly Cited
1999
Highly Cited
1999
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.
PURPOSE Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and… 
Highly Cited
1998
Highly Cited
1998
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
PURPOSE To compare two doses of letrozole and megestrol acetate (MA) as second-line therapy in postmenopausal women with advanced… 
Highly Cited
1998
Highly Cited
1998
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma
This report presents the results of a survival update based on the combined data from two studies that compared the efficacy and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License